Oralome Inc — Department of Defense SBIR Phase I: AF203-CSO1
Oralome Inc — SBIR Phase I award from Department of Defense.
- Amount
- $49,975
- Agency
- Department of Defense · Air Force
- Program / Phase
- SBIR · Phase I
- Topic
- AF203-CSO1
- Solicitation
- X20.3
- NAICS
- —
- Place of performance
- CA
- Period
- 2021-02-05 → 2021-05-03
Description
Oralome risk assessment platform for infections of respiratory system is the most comprehensive risk assessment tool available that profiles more than 500 bacteria and viruses in a single saliva test. Our test is based on next generation DNA sequencing technology and meta-transcriptomics. It guides Air Force clinicians in: a. Quickly identifying the type of infection (viral and/or bacterial) for patients with respiratory symptoms including COVID-19; and b. Identifying the correct regiment of antiviral/antibiotic treatment, based on the test results. c. Early detection of emerging and new infections.